Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE

• Published in: Nature biotechnology
• Main Authors: Song, Jayeon, Cho, Mi Hyeon, Cho, Hayoung, Song, Younseong, Lee, Sung Woon, Nam, Ho Chul, Yoon, Tae Ho, Shin, Jong Cheol, Hong, Jae-Sang, Kim, Yejin, Ekanayake, Emil, Jeon, Jueun, You, Dong Gil, Im, Sung Gap, Choi, Gyu-Seog, Park, Jun Seok, Carter, Bob C, Balaj, Leonora, Seo, An Na, Miller, Miles A, Park, Soo Yeun, Kang, Taejoon, Castro, Cesar M, Lee, Hakho
• Format: Journal Article
• Language: English
• Published: United States 07.10.2024
• ISSN: 1087-0156; 1546-1696; 1546-1696
• DOI: 10.1038/s41587-024-02426-6

Sequencing of messenger RNA (mRNA) found in extracellular vesicles (EVs) in liquid biopsies can provide clinical information such as somatic mutations, resistance profiles and tumor recurrence. Despite this, EV mRNA remains underused due to its low abundance in liquid biopsies, and large sample volumes or specialized techniques for analysis are required. Here we introduce Self-amplified and CRISPR-aided Operation to Profile EVs (SCOPE), a platform for EV mRNA detection. SCOPE leverages CRISPR-mediated recognition of target RNA using Cas13 to initiate replication and signal amplification, achieving a sub-attomolar detection limit while maintaining single-nucleotide resolution. As a proof of concept, we designed probes for key mutations in KRAS, BRAF, EGFR and IDH1 genes, optimized protocols for single-pot assays and implemented an automated device for multi-sample detection. We validated SCOPE's ability to detect early-stage lung cancer in animal models, monitored tumor mutational burden in patients with colorectal cancer and stratified patients with glioblastoma. SCOPE can expedite readouts, augmenting the clinical use of EVs in precision oncology.